publication date: Oct. 4, 2019

Drugs & Targets

Keytruda approved as monotherapy in China for NSCLC

The National Medical Products Administration in China approved Merck’s Keytruda as monotherapy for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer whose tumors express PD-L1, with no EGFR or ALK genomic tumor aberrations.

Keytruda is the first anti-PD-1 therapy approved in China as both monotherapy and in combination with chemotherapy for the first-line treatment of patients with NSCLC.

Copyright (c) 2019 The Cancer Letter Inc.